Toxicology & Biomaterials · PVC Safety

Toxicological Risks of DEHP Plasticizer Leaching in Infusion Therapy

A clinical examination of di(2-ethylhexyl)phthalate (DEHP) leaching kinetics from standard polyvinyl chloride (PVC) medical tubing, vulnerable patient populations, and polyolefin materials solutions.

Clinical Peer Review: Marcus Finch, PharmD, BCPPS, BCSCP Published: October 2026 Verified Board Member →

1. Toxicology & Physicochemical Leaching Kinetics

Di(2-ethylhexyl) phthalate (DEHP) is a synthetic chemical plasticizer incorporated into Polyvinyl Chloride (PVC) formulations in concentrations up to 40% by weight to render rigid plastic flexible. Because DEHP is physically dispersed within the polymer matrix rather than covalently bound, it readily leaches into lipid-containing solutions, lipophilic medications, and surfactant-containing drug formulations.

Once absorbed systemically, DEHP is metabolized into mono(2-ethylhexyl) phthalate (MEHP). These active metabolites act as peroxisome proliferator-activated receptor (PPAR) agonists and endocrine disruptors, causing testicular atrophy, altered thyroid signaling, hepatotoxicity, and cardiopulmonary dysfunction.

2. High-Risk Populations & Chemotherapy Vehicles

Certain patient cohorts and pharmacological formulations present severe clinical risk for massive DEHP exposure:

TABLE 1: DEHP LEACHING SUSCEPTIBILITY BY DRUG FORMULATION
FDA Safety Assessment · Biomaterial Guidelines
Infusion Solution / Drug Leaching Vehicle / Surfactant DEHP Leached from PVC Recommended Non-PVC Material Authority
Paclitaxel (Taxol®) Polyoxyethylated castor oil (Cremophor EL) Extreme (>150 µg/mL) Polyethylene-lined PVC or Polyolefin sets FDA Label / INS
Docetaxel (Taxotere®) Polysorbate 80 (Tween 80) High (>50 µg/mL) Pure Polyethylene / Polyurethane infusion sets FDA Drug Label
Lipid Injectable Emulsion (ILE) Soybean / olive / fish oil triglycerides Moderate to High Multi-layer co-extruded Polyolefin / EVA bags ASPEN / Eur. Pharm.
Nitroglycerin / Diazepam Lipophilic formulation (sorption loss) >40–80% Drug Loss to PVC Glass containers + Polyethylene-lined sets USP Guidelines

3. Engineering Solutions: Polyolefin & Polyethylene Systems

To protect vulnerable neonatal, pediatric, and adult oncology populations from plasticizer toxicities, healthcare institutions must transition to non-PVC and DEHP-free materials:

  • Co-Extruded Polyethylene (PE)-Lined Tubing: Features an inert polyethylene inner lumen that prevents drug sorption and completely halts plasticizer leaching, surrounded by an outer polyurethane shell for flexibility.
  • Polyolefin & Ethyl Vinyl Acetate (EVA): Completely plasticizer-free polymers widely utilized for Total Parenteral Nutrition bags and high-volume infusion sets.
  • Silicone Elastomer Lines: Inert, highly biocompatible catheter materials utilized in long-term PICCs and implanted central vascular ports.

Evidence Base & Literature Citations

  1. Tickner JA, et al. Health risks posed by exposure to di-2-ethylhexyl phthalate in healthcare settings: A review of the literature. Am J Ind Med. 2001;39(1):100-111. DOI: 10.1002/ajim.10002
  2. U.S. Food and Drug Administration (FDA). Safety Assessment of Di(2-ethylhexyl)phthalate (DEHP) Released from PVC Medical Devices. Center for Devices and Radiological Health; 2001.
  3. Mallow EB, Savelyev MA. DEHP Leaching From Infusion Sets in Critical Care: Systematic Literature Review. J Infus Nurs. 2017;40(6):368-376. DOI: 10.1097/NAN.0000000000000251

Clinical Practice Boundary Notice

This protocol provides evidence-based guidance reflecting INS 2024 Standards of Practice and CDC recommendations. Clinical judgment, institutional policy, and patient-specific variables must guide individualized bedside care.